Postherpetic neuralgia Mental and Behavioural Disorders Cranial nerve disorders in diseases classified elsewhere
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age greater than 60 years 2. Weighs over 40kg 3. History of pain is longer than 3 months 4. Pain on Visual Analogue Scale (VAS) >3 (0-10 VAS scale), with acute pain flares that occurred more than 3 times per day 5. Refractory to formal treatment such as antiepileptic medicine, antidepressants, opioids, physical treatments and epidural block 6. No history of severe liver and renal diseases 7. PHN patents whose pain area was at T1-12 level 8. Male and female participants
Exclusion criteria
Exclusion criteria: 1. Withdraws from the study 2. Poor effect, intolerant to the study 3. Uncooperative and unable to finish the self evaluation (VAS, QOL and SF-36) 4. Coagulation disturbances 5. Allergies to drug 6. Malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. fMRI signal change, IGT results at baseline and 14 days after treatment 2. Visual Analogue Scale (VAS), measured at baseline and 1, 2, 3,7 and 14 days after treatment 3. Pain flare-ups per day during days 3, 7, 14 after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. SF-36 at baseline, 14 days after treatment 2. Dosage of rescue drug (Oxycodone) consumed per day at 3, 7, and 14 days after treatment 3. Presence, frequency and duration of adverse effects at 7 and 14 days after treatment | — |
Countries
China